This Article Full Text Full Text (PDF) Correction (v16,p1042) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jain, M. Articles by Mittal, B. Search for Related Content PubMed PubMed Citation Articles by Jain, M. Articles by Mittal, B.

Role of GSTM3 Polymorphism in the Risk of Developing Esophageal Cancer

Departments of ¹ Medical Genetics, ² Radiotherapy, and ³ Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Requests for reprints: Balraj Mittal, Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareilly Road, Lucknow 226014, India. Phone: 91-522-2668973, ext. 2322; Fax: 91-522-2668017/2668074. E-mail: balraj{at}sgpgi.ac.in or bml_pgi{at}yahoo.com

GSTM3 is involved in detoxification of carcinogens and may be important in modulating cancer susceptibility. GSTM3 genotype frequencies were determined in peripheral blood DNA of 149 esophageal cancer patients and 200 nonmalignant controls using the PCR followed by PAGE. Patients who were heterozygous carriers of GSTM3 AB genotype had an enhanced risk for developing esophageal cancer [odds ratio (OR), 2.1; 95% confidence interval (95% CI), 1.1-3.7; P = 0.01]. In males, the risk due to GSTM3 AB genotype increased further (OR, 3.4; 95% CI, 1.7-6.8; P = 0.000). Interaction of GSTM3 AB + BB and GSTM1 null genotypes marginally modulated risk (OR, 2.3; 95% CI, 1.1-3.7; P = 0.01). Association with histology (adenocarcinoma: OR, 3.4; 95% CI, 1.1-10.9; P = 0.03) and tumor site (middle third location: OR, 2.2; 95% CI, 1.1-4.4; P = 0.01; lower third location: OR, 2.6; 95% CI, 1.2-5.6; P = 0.01) was also documented. Our results suggest that GSTM3 polymorphism may influence esophageal cancer susceptibility, in particular modulating the risk for adenocarcinoma histology and tumors of the mid and lower third region. (Cancer Epidemiol Biomarkers Prev 2007;16(1):178–81)

This article has been cited by other articles:

				Corrections Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1042 - 1042. [Full Text] [PDF]